28 April 2021 in Journal of Experimental Medicine
Safe and effective coronavirus disease–19 (COVID-19) vaccines are urgently needed to control the ongoing pandemic. While single-dose vaccine regimens would provide multiple advantages, two doses may improve the magnitude and durability of immunity and protective efficacy. We assessed one- and two-dose regimens of the Ad26.COV2.S vaccine candidate in adult and aged nonhuman primates (NHPs). A two-dose Ad26.COV2.S regimen induced higher peak binding and neutralizing antibody responses compared with a single dose. In one-dose regimens, neutralizing antibody responses were stable for at least 14 wk, providing an early indication of durability. Ad26.COV2.S induced humoral immunity and T helper cell (Th cell) 1–skewed cellular responses in aged NHPs that were comparable to those in adult animals. Aged Ad26.COV2.S-vaccinated animals challenged 3 mo after dose 1 with a SARS-CoV-2 spike G614 variant showed near complete lower and substantial upper respiratory tract protection for both regimens. Neutralization of variants of concern by NHP sera was reduced for B.1.351 lineages while maintained for the B.1.1.7 lineage independent of Ad26.COV2.S vaccine regimen.
19 May 2023 in Immunology Letters
Autoimmune diseases are heterogeneous pathologies characterized by a breakdown of immunological tolerance to self, resulting in a chronic and aberrant immune response to self-antigens. The scope and extent of affected tissues can vary greatly per autoimmune disease and can involve multiple organs and tissue types. The pathogenesis of most autoimmune diseases remains unknown but it is widely accepted that a complex interplay between (autoreactive) B and T cells in the context of breached immunological tolerance drives autoimmune pathology. The importance of B cells in autoimmune disease is exemplified by the successful use of B cell targeting therapies in the clinic. For example, Rituximab, a depleting anti-CD20 antibody, has shown favorable results in reducing the signs and symptoms of multiple autoimmune diseases, including Rheumatoid Arthritis, Anti-Neutrophil Cytoplasmic Antibody associated vasculitis and Multiple Sclerosis. However, Rituximab depletes the entire B cell repertoire, leaving patients susceptible to (latent) infections. Therefore, multiple ways to target autoreactive cells in an antigen-specific manner are currently under investigation. In this review, we will lay out the current state of antigen-specific B cell inhibiting or depleting therapies in the context of autoimmune diseases.
19 May 2025 in Nature Communications
Clinical responses with chimeric antigen receptor (CAR) T cells are encouraging, but primary resistance and relapse after therapy prevent durable remission in many patients with cancer, with apoptosis resistance in cancer cells that limits killing by CAR T cells being a potential cause. Here we aim to boost tumor cell apoptosis induced by CAR T cells and find that anti-B cell maturation antigen (BCMA) CAR T cells over-expressing a granzyme B-NOXA fusion protein show improved killing of multiple myeloma (MM) cells in vitro and in xenograft mouse models in vivo. Mechanistically, such an enhancement is mediated by localizing NOXA to cytotoxic granules that are released into cancer cells upon contact. In MM cells, inhibition of MCL-1, an anti-apoptotic factor, by its natural ligand NOXA effectively induces apoptosis. Our data thus show that endowing granzyme B-NOXA expression to CAR T cells improves their killing efficacy, thereby presenting a potential generalizable enhancement for CAR T-mediated anti-cancer immunity.
16 January 2025 in European Journal of Immunology
Many human autoimmune diseases (AIDs) are hallmarked by the presence and persistence of autoreactive B‐cells. While autoreactive B‐cells may frequently encounter antigens, the signals required to balance and maintain their activation and survival are mostly unknown. Understanding such signals may be important for strategies aimed at eliminating human B‐cell autoreactivity. Here, we assessed intracellular signaling pathways in B cells targeting citrullinated protein antigens isolated from patients with rheumatoid arthritis (RA), a common and well‐characterized AID. Peripheral blood mononuclear cells of 15 RA patients positive for anti‐citrullinated protein antibodies (ACPA) were analyzed directly ex vivo using spectral flow cytometry and B‐cell differentiation markers, citrullinated antigen‐biotin‐streptavidin tetramers, and intracellular (phosphoflow) markers. Tetanus toxoid (TT)‐specific B cells served as antigen‐specific comparators. In absence of any in vitro BCR stimulation, ACPA‐expressing memory B cells (MBCs) displayed enhanced expression of Ki‐67 and increased SYK‐, BTK‐, AKT‐, and S6‐phosphorylation compared with TT‐specific MBCs. We demonstrate the simultaneous detection of B cell antigen‐specificity and intracellular protein phosphorylation on the single‐cell level. The data reveal that autoreactive B‐cells in RA, in contrast to B cells against recall antigens, display enhanced phosphorylation of signaling molecules that point toward continuous, presumably antigen‐mediated activation of the autoreactive B‐cell compartment.
29 April 2026 in Annals of the Rheumatic Diseases
Rheumatoid arthritis, a prototypic autoimmune disease, is characterised by the presence of anticitrullinated protein antibodies (ACPAs). Unlike responses to recall antigens, ACPA-expressing B cells display a continuous phenotype of recent activation, even in patients with sustained clinical remission, indicating that these cells are continuously activated over long periods without 'dying out' or acquiring a resting or anergic phenotype. To elucidate whether this persistent activation reflects ongoing stimulation of the same B cell clones or recruitment of new cells, we longitudinally analysed ACPA B cell dynamics. ACPA-expressing B cells were isolated using tetramer-based flow cytometry. One thousand five hundred eighty-one B cell receptor sequences were determined by Smart-Seq2-based immunoglobulin-gene amplification and paired heavy/light-chain Sanger sequencing. Antigen reactivity was validated by producing and testing 414 monoclonal antibodies. The data obtained show that ACPA repertoires are polyclonal with oligoclonal expansions and skewed variable gene usage, increased lambda-to-kappa ratios, and extensive somatic mutations. Clonal phylogenetic analysis revealed the presence of highly mutated clones persisting over time, coexisting with newly appearing, lowly mutated expanded families. Remarkably, multiple clonal families could be traced over a period of 8 years. These observations demonstrate that the ACPA-expressing B cell population includes persistent and newly recruited cells that together fuel this ongoing autoimmune response. These data provide insights into B cell autoreactivity and its seemingly exhaustless persistence in a prominent human autoimmune disease by indicating that human autoreactive B cell populations are not static but continuously reshape under chronic antigen stimulation.
5 March 2026 in Nature Communications
Although N-linked glycans play pivotal roles in the regulation of antibody effector functions, little is known about the composition and functional impact of glycans attached to human B cell receptors (BCR). Here, we describe the site-specific glycosylation profiles of all 4 N-linked glycosylation sites of human Igµ BCRs from primary naive and memory B cells. Our data indicate that the Igµ BCR glycans do not undergo structural changes during transition from naive to memory cells, as healthy donor-derived BCRs from both B cell subtypes carry similar glycans. Conversely, serum IgM antibodies display distinct glycosylation features to Igµ BCRs, which are in part explained by the different molecular form of Igµ BCRs and IgM antibodies. Moreover, using B cell lines expressing defined BCRs, we show that, although the absence of the Igµ BCR N209 glycans reduces antigen binding, the individual glycosylation sites are nonessential for cell surface expression and BCR internalization following BCR triggering. Collectively, we show high conservation of Igµ BCR glycosylation across B cell subsets and limited contribution to BCR expression and function, suggesting BCR glycans may have evolved to support IgM antibody functions.